参考文献

［1］SCHUSTER D M，NANNI C，FANTI S. PET tracers beyond FDG in prostate cancer［J］. Semin Nucl Med，2016，46（6）：507-521.

［2］CALAIS J，CECI F，EIBER M，et al. ¹⁸ F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy：a prospective，single-centre，single-arm，comparative imaging trial［J］. Lancet Oncol，2019，20（9）：1286-1294.

［3］LANGSTEGER W，REZAEE A，PIRICH C，et al. ¹⁸ F-NaF-PET/CT and 99mTc-MDP Bone Scintigraphy in the Detection of Bone Metastases in Prostate Cancer［J］. Semin Nucl Med. 2016，46（6）：491-501.

［4］FENDLER W P，EIBER M，BEHESHTI M，et al. ⁶⁸ Ga-PSMA PET/CT：Joint EANM and SNMMI procedure guideline for prostate cancer imaging：version 1. 0［J］. Eur J Nucl Med Mol Imaging. 2017，44（6）：1014-1024.

［5］SAWICKI L M，KIRCHNER J，BUDDENSIECK C，et al. Prospective comparison of whole-body MRI and ⁶⁸ Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy［J］.Eur J Nucl Med Mol Imaging. 2019，46（7）：1542-1550.

［6］MOTTET N，VAN DEN BERGH RCN，BRIERS E，et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. part 1：screening，diagnosis，and local treatment with curative intent［J］. Eur Urol. 2021，79（2）：243-262.

［7］HOFMAN M S，LAWRENTSCHUK N，FRANCIS R J，et al. Prostate-specific membrane antigen PETCT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy（proPSMA）：a prospective，randomised，multicentre study［J］. Lancet. 2020，395（10231）：1208-1216.

［8］EIBER M，HERRMANN K，CALAIS J，et al. Prostate cancer molecular imaging standardized evaluation（PROMISE）：proposed miTNM classification for the Interpretation of PSMA-Ligand PET/CT［J］. J Nucl Med，2018，59（3）：469-478.

［9］ROWE S P，PIENTA K J，POMPER M G，Gorin M A. PSMA-RADS Version 1. 0：a step towards standardizing the interpretation and reporting of psma-targeted pet imaging studies［J］. Eur Urol，2018，73（4）：485-487.

［10］GRUBMÜLLER B，BALTZER P，HARTENBACH S，et al. PSMA ligand pet/mri for primary prostate cancer：staging performance and clinical impact［J］. Clin Cancer Res，2018，24（24）：6300-6307.

［11］PHILLIPS R，SHI W Y，DEEK M，et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer：the ORIOLE phase 2 randomized clinical trial［J］. JAMA Oncol，2020，6（5）：650-659.

［12］EMMETT L，BUTEAU J，PAPA N，et al. The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer（PRIMARY）：a prospective multicentre study［J］. Eur Urol，2021，80（6）：682-689.

［13］MEISSNER V H，RAUSCHER I，SCHWAMBORN K，et al. Radical prostatectomy without prior biopsy following multiparametric magnetic resonance imaging and prostate-specific membrane antigen positron emission tomography［J］. Eur Urol，2022，82（2）：156-160.

［14］AYDOS U，ÇETIN S，AKDEMIR ÜÖ，et al. The role of histopathological and biochemical parameters for predicting metastatic disease on ⁶⁸ Ga-PSMA-11 PET in prostate cancer［J］. Prostate，2021，81（16）：1337-1348.

［15］李亚健，彭博施张，王远卓，等. ⁶⁸ Ga-PSMA PET/CT在前列腺癌术前诊断及手术策略制订中的应用［J］. 中华泌尿外科杂志，2021，42（1）：12-17. N3wj0cEHSsUqQjXohr60tFlMtJBUUvAoxMgwpX44havpD57/LMrY6OOSmxQrKe7q